Insights in regulated bioanalysis of human insulin and insulin analogs by immunoanalytical methods

Bioanalysis

Volumn 3, Issue 8, 2011, Pages 883-898

  Bowsher, Ronald R ^a,b   Nowatzke, William L ^c  

^a B2S Consulting   (United States)

^b Bioscience Division   (United States)

^c Worldwide Clinical Trials   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN DERIVATIVE;

ANALYTIC METHOD; ANTIBODY SPECIFICITY; ANTIGEN FUNCTION; CALIBRATION; DRUG DISPOSITION; DRUG METABOLISM; EPITOPE MAPPING; HORMONE STRUCTURE; HUMAN; IMMUNOASSAY; INSULIN METABOLISM; NONHUMAN; PRACTICE GUIDELINE; PROTEIN POLYMORPHISM; QUALITY CONTROL; REVIEW; STRUCTURE ANALYSIS; VALIDATION PROCESS;

HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOASSAY; INSULIN; PHARMACOKINETICS;

EID: 79955437101     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.50     Document Type: Review

References (141)

1. Bliss M. The Discovery of Insulin. McClellad & Stewart Limited, Toronto, Canada (1982).
2. Rosenfeld L. Insulin. Discovery and controversy. Clin. Chem. 48, 2270-2288 (2002).
3. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher A. Pancreatic extracts in the treatment of diabetes mellitus. A preliminary report. Can. Med. Assoc. J. 12(3), 141-146 (1922).
4. Also see Encore publication in Can. Med. Assoc. J. 145(10), 1281-1286.
5. Berson SA, Yalow RS, Bauman A, Rothchild MS, Newerly K. Insulin-I131 metabolism in human subjects. demonstration of insulin binding globulin in the circulation of insulin treated subjects. J. Clin. Invest. 35, 170-190 (1956).
6. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J. Clin. Invest. 39, 1157-1175 (1960).
7. Kahn CR, Roth J. Berson, Yalow and the JCI. the agony and the ecstacy. J. Clin. Invest. 114(8), 1051-1054 (2004).
8. Yalow RS. Radioimmunoassay. A probe for the fine structure of biologic systems. Science 200(4347), 1236-1245 (1978). (Pubitemid 8405750)
9. Berson SA, Yalow RS. General principles of radioimmunoassay. 1968. Clin. Chim. Acta 369(2), 125-143 (2006).
10. Blumenthal S. The insulin immunoassay after 50 years. A reassessment. Perspect. Biol. Med. 52(3), 343-354 (2009).
11. Johnson IS. Human insulin from recombinant DNA technology. Science 219(4585), 632-637 (1983). (Pubitemid 13185414)
12. Chance RE, Frank BH. Research, development, production and safety of biosynthetic human insulin. Diabetes Care 16(Suppl. 3), 133-142 (1993). (Pubitemid 23348328)
13. Ladisch MR, Kohlmann KL. Recombinant human insulin. Biotechnol. Prog. 8(6), 469-478 (1992).
14. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975).
15. Martinis J, David GS, Bartholomew RM, Wang R. Novel applications of monoclonal antibodies. Basic Life Sci. 25, 129-154 (1983).
16. Payne WJ, Marshall DL, Shockley RK, Martin WJ. Clinical laboratory applications of monoclonal antibodies. Clin. Microbiol. Rev. 1(3), 313-329 (1988).
17. Borrebaeck CA. Antibodies in diagnostics - from immunoassays to protein chips. Immunol. Today 21(8), 379-382 (2000). (Pubitemid 30612298)
18. Tolvonen E, Hemmila I, Marniemi J, Jorgensen PN, Zeuthen J, Lovgren T. Two-site time-resolved immunoflourometric assay of human insulin. Clin. Chem. 32, 637-640 (1986). (Pubitemid 17027204)
19. Comitti R, Racchetti G, Guocchi P, Marandi E, Galeuti YM. A monoclonal based two-site enzyme immunoassay for human insulin. J. Immunol. Methods 99, 25-37 (1987). (Pubitemid 17089971)
20. Burgi W, Briner M, Franken N, Kessler AC. One-step sandwich enzyme immunoassay for insulin using monoclonal antibodies. Clin. Biochem. 21(5), 311-314 (1988).
21. Sobey WJ, Beer SF, Carrington CA et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin 65-66 split and 32-33 split proinsulins. Biochem. J. 260, 535-541 (1989). (Pubitemid 19151101)
22. Alpha B, Cox L, Crowther N, Clark PMS, Hales CN. Sensitive amplified immunoenzymometric assays (IEMA) for human insulin and intact proinsulin. Eur. J. Clin. Chem. Clin. Biochem. 30, 27-32 (1992).
23. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzymeimmunoassay for intact human insulin in serum or plasma. Clin. Chem. 39, 578-582 (1993). (Pubitemid 23118305)
24. Clark PMS, Hales CN. How to measure plasma insulin. Diabetes Metab. Rev. 10(2), 79-90 (1994). (Pubitemid 24252908)
25. Deberg M, Houssa P, Frank BH, Sodoyez-Goffaux F, Sodoyez JC. Highly specific radiommunoassay for human insulin based on immune exclusion of all insulin precursors. Clin. Chem. 44, 1504-1513 (1998). (Pubitemid 28309112)
26. Robbins DC, Andersen L, Bowsher R et al. Task Force Report. Report of the American Diabetes Association's task force on standardization of the insulin assay. Diabetes 45, 242-256 (1996).
27. Marcovina S, Bowsher RR, Miller WG et al. Standardization of insulin immunoassays. Report of the American Diabetes Association Workgroup. Clin. Chem. 53, 711-716 (2007). (Pubitemid 46580242)
28. Miller WG, Thienpont LM, Van Uytfanghe K et al. Clin Chem 55(5), 1011-1018 (2009).
29. Chevenne D, Trivin F, Porquet D. Insulin assay and reference values. Diabetes & Metabolism (Paris) 25, 459-476 (1999).
30. Young FG. Experimental research on diabetes mellitus. Br. Med. J. 2(5265), 1449-1454 (1961).
31. Peterson JD, Steiner DF. The amino acid sequence of the insulin from a primitive vertebrate, the Atlantic hagfish (Myxine glutinosa). J. Biol. Chem. 250(13), 5183-5191 (1975).
32. Shuldiner AR, Bennet C, Robinson EA, Roth J. Isolation and characterization of two different insulins from an amphibian, Xenopus laevis. Endocrinol. 125, 469-477 (1989). (Pubitemid 19182696)
33. Clark JL, Steiner DF. Insulin biosynthesis in the rat. Demonstation of two proinsulins. Proc. Natl Acad. Sci. USA 62(1), 278-285 (1969).
34. Zimmerman AE, Yip CC. Guinea pig insulin I, purification and physical properties. J. Biol. Chem. 249(13), 4021-4025 (1974).
35. Wentworth BM, Schaefer IM, Villa-Komaroff L, Chirgwin JM. Characterization of the two nonallelic genes encoding mouse proinsulin. J. Mol. Evol. 23, 305-312 (1986). (Pubitemid 17065031)
36. Findlay JWA, Smith WC, Lee JW et al. Validation of immunoassays for bioanalysis. A pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21, 1249-1273 (2000). (Pubitemid 30001554)
37. Tate J, Ward G. Interferences in immunoassay. Clin. Biochem. Rev. 25, 105-120 (2004).
38. Jones AM, Honour JW. Unusual results from immunoassays and the role of the clinical endocrinologist. Clin. Endocrinol. 64, 234-244 (2006).
39. Clark PM. Assays for insulin, proinsulin(s) and C-peptide. Ann. Clin. Biochem. 36, 541-564 (1999). (Pubitemid 29410707)
40. Sapin R. Insulin assays. previously known and new analytical features. Clin. Lab. 49(3-4), 113-121 (2003). (Pubitemid 36504088)
41. Sapin R. Insulin immunoassays. Fast approaching 50 years of existence and still calling for standardization. Clin. Chem. 53(5), 810-812 (2007). (Pubitemid 46744234)
42. Shah VP, Midha KK, Dighe S et al. Analytical methods validation. Bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Pharm. Res. 9(4), 588-592 (1992).
43. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003). (Pubitemid 37449466)
44. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation. Best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007). (Pubitemid 47389236)
45. Hannon WH, Atkinson MA, Ball DJ et al. Assessing the quality of immunoassay systems. Radioimmunoassay and enzyme, fluorescence, and luminescence immunoassays; approved guideline. CLSI I/ LA23-A 24(16), 1-36 (2004).
46. Lee JW, Devanarayan V, Barrett Y-C et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006). (Pubitemid 43237862)
47. Kricka LJ, Master SR. Validation and quality control of protein microarray-based analytical methods. Mol. Biotechnol. 38, 29-31 (2008).
48. Warnick GR, Kimberly MM, Waymack PP, Leary ET, Myers GL. Standardization of measurements for cholesterol, triglycerides, and major lipoproteins. Labmedicine 39(8), 481-490 (2008).
49. Jennings L, VanDeerlin VM, Gulley ML. Recommended principles and practices for validating clinical molecular pathology tests. Arch. Pathol. Lab. Med. 133, 743-755 (2009).
50. Organization for Economic Co-operation development. OECD series on principles of Good Laboratory Practice and compliance monitoring number 4 (revised). GLP consensus document. Quality Assurance and GLP environment directorate. Organization for economic co-operation development, Paris (1999).
51. Miller KJ, Bowsher RR, Celniker A et al. Workshop on bioanalytical methods validation for macromolecules. Summary report. Pharm. Res. 18(9), 1373-1383 (2001). (Pubitemid 32846335)
52. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Meth. 289(1-2), 1-16, (2004). (Pubitemid 38900899)
53. Gupta S, Indelicato S, Jethwa V et al. Recommendation for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutic. J. Immunol. Meth. 321, 1-18, (2007). (Pubitemid 46454303)
54. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008).
55. Abbott R. The broadening scope of validation. Towards best practices in the world of bioanalysis. Bioanalysis 2(4), 703-708 (2010).
56. Heinemann L. Insulin assay standardization. leading to measure of insulin sensitivity and secretion for practical clinical care. Diabetes Care 33(6), e83 (2010).
57. Staten MA, Miller WG, Bowsher RR, Steffes MW. Insulin assay standardization. leading to measure of insulin sensitivity and secretion for practical clinical care. Diabetes Care 33(6), E84 (2010).
58. Volund A, Brange J, Drejer K et al. In vitro and in vivo potency of insulin analogs designed for clinical use. Diabetic Med. 8, 839-847 (1991).
59. Volund A. Conversion of insulin units to SI units. Am. J. Clin. Nutr. 58(5), 714-715 (1993).
60. DiMarchi RD, Chance RE, Long HB, Shields JE, Slieker LJ. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm. Res. 4(Suppl. 2), 93-96 (1994). (Pubitemid 24180905)
61. Brange J. The new era of biotech insulin analogs. Diabetologia 40, S48-S53 (1997). (Pubitemid 27306922)
62. Lee WL, Zinman B. From insulin to insulin analogs. progress in the treatment of type 1 diabetes. Diabetes Rev. 6(2), 73-88 (1998). (Pubitemid 28554675)
63. Bolli GB, DiMarchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogs and their potential in the management of diabetes mellitus. Diabetologia 42, 1151-1167 (1999). (Pubitemid 29459810)
64. Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv. Drug Del. Rev. 35, 307-335 (1999). (Pubitemid 29073621)
65. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 22(Suppl. 2), B109-B113 (1999). (Pubitemid 29107159)
66. Vajo Z, Duckworth WC. Genetically engineered insulin analogs. diabetes in the new millennium. Pharmacol. Rev. 52(1), 1-9 (2000). (Pubitemid 30127592)
67. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes. insulin analogs. Endocr. Rev. 22, 706-717 (2001). (Pubitemid 32955251)
68. Simpson SH, Toth EL. Expanding the options in insulin therapy. a review of insulin analogs. Can. J. Diabetes 26(3), 195-205 (2002).
69. Zinman B. Effective use of insulin therapy in Type 2 diabetes. Adv. Stud. Med. 2(26), 954-960 (2002).
70. Owens DR, Bolli GB. Beyond the era of NPH insulin - long-acting insulin analogs. chemistry, comparative pharmacology, and clinical application. Diabetes Technol. Therap. 10(8), 333-349 (2008).
71. Roach P. New insulin analogs and routes of delivery. Pharmacodynamic and clinical considerations. Clin. Pharmacokinet. 47(9), 595-610 (2008).
72. Galloway JA. Chemistry and clinical use of insulin, Chapter 7. In. Diabetes Mellitus, 9th Edition. Galloway JA, Potvin JH, Shuman CR (Eds), Lilly Research Lab., IN, USA 106-133 (1988).
73. Heller S, Kozlovski P, Kurtzhals P. Insulin's 85th anniversary - an enduring medical miracle. Diabet. Res. Clin. Prac. 78, 149-158 (2007). (Pubitemid 47451532)
74. Laube BL. Treating diabetes with aerosolized insulin. Chest 120(3 Suppl.), 99S-106S (2001). (Pubitemid 32881571)
75. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet. Med. 20(11), 886-898 (2003). (Pubitemid 41701487)
76. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28),Pro(B29)]- human insulin. A rapidly absorbed analog of human insulin. Diabetes 43, 396-402 (1994). (Pubitemid 24064246)
77. Holleman F, Hoekstra JB. Insulin lispro. NEJM 337(3), 176-183 (1997). (Pubitemid 27306290)
78. Chance RE, Frank BH, Radziuk JM, DiMarchi RD. Discovery and development of insulin lispro. Drugs Today 34(Suppl. C), 1-9 (1998). (Pubitemid 28238099)
79. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analog. Human insulin B28Asp. Diabet. Med. 10(6), 535-539 (1993). (Pubitemid 23189758)
80. Simpson KL, Spencer CM. Insulin Aspart. Drugs 57(5), 759-765 (1999).
81. Garg SK, Ellis SL, Ulrich H. Insulin glulisine. A new rapid-acting insulin analog for the treatment of diabetes. Expert Opin. Pharmacolther. 6(4), 643-651 (2005). (Pubitemid 40613890)
82. Garnock-Jones KP, Plosker GL. Insulin glulisine. A review of its use in the management of diabetes mellitus. Drugs 69(8), 1035-1057 (2009).
83. Wang F, Carabino JM, Vergara CM. Insulin glargine. A systematic review of a long-acting insulin analog. Clin. Ther. 25(6), 1541-1577 (2003). (Pubitemid 36801936)
84. Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs 59(2), 253-260 (2000). (Pubitemid 30168511)
85. Bolli GB, Owens DR. Insulin glargine. Lancet 356(9228), 443-445 (2000). (Pubitemid 30496809)
86. Heinemann L, Sinha K, Weyer C et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analog NN304. Diabet. Med. 16(4), 332-338 (1999).
87. Dea MK, Hamilton-Wessler M, Ader M et al. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes 51, 762-769 (2002). (Pubitemid 34760186)
88. Home P, Kurtzhals P. Insulin detemir. From concept to clinical experience. Expert Opin. Pharmacother. 7(3), 325-343 (2006). (Pubitemid 43263250)
89. Sirkka-Liisa K, Melamies L, Kostamo E, Poyry K. Problems in the determination of short-acting insulin analog by commercial insulin kits. Diabetes 44(Suppl. 1), 229A (1995).
90. Sapin R, LeGaludec V, Gasser F, Pinget M, Grucker D. Elecsys insulin assay. Free insulin determination and the absence of crossreactivity with insulin lispro. Clin. Chem. 47(3), 620-605 (2001).
91. Sapin R. Insulin assays. Previously known and new analytical features. Clin. Lab. 49(3-4), 113-121 (2003). (Pubitemid 36504088)
92. Owen WE, Roberts WL. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin. Chem. 50(1), 257-259 (2004). (Pubitemid 38125742)
93. Moriyama M, Nobuhide H, Ohyabu C et al. Performance evaluation and crossreactivity from insulin analogs with the ARCHITECT insulin assay. Clin. Chem. 52(7), 1423-1426 (2006). (Pubitemid 43956037)
94. Heald AH, Bhattacharya B, Cooper H et al. Most commercial insulin assays fail to detect recombinant insulin analogs. Ann. Clin. Biochem. 43(Pt 4), 306-308 (2006). (Pubitemid 44049695)
95. Song D, Davidson J. Cross-reactivity of Actrapid® and three insulin analogs in the Abbot IMX insulin immunoassay. Ann. Clin. Biochem. 44(Pt 2), 197-198 (2007). (Pubitemid 46525020)
96. Neal JM, Han W. Insulin immunoassays in the detection of insulin analogs in factitious hypoglycemia. Endocr. Pract. 14(8), 1006-1010 (2008).
97. Bowsher RR, Lynch RA, Brown-Augsburger P et al. Sensitive RIA for the specific determination of insulin lispro. Clin. Chem. 45(1), 104-110 (1999). (Pubitemid 29036392)
98. Andersen L, Jorgensen PN, Jensen LB, Walsh D. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence and pharmacokinetic studies. Clin. Biochem. 33(8), 627-633 (2000). (Pubitemid 32146198)
99. Holloway DL, Santa PF, Compton JA, Bowsher RR. Humalog, a rapidly absorbed analog of human insulin, determined with Coat-A-Count insulin radioimmunoassy. Clin. Chem. 41(12 Pt 1), 1777-1778 (1995). (Pubitemid 3011965)
100. Andersen L, Volund A, Olsen KJ, Plum A, Walsh D. Validity and use of a non-parallel insulin assay for pharmacokinetic studies of the rapid-acting insulin analog, insulin aspart. J. Immunoassay Immunochem. 22(2), 147-163 (2001). (Pubitemid 32721182)
101. Chance RE, Root MA, Galloway JA. The immunogenicity of insulin preparations. Acta Endocrinol. Suppl. (Copenh.) 205, 185-198 (1976).
102. Barcinski MA, Rosenthal AS. Immune response gene control of determinant selection. I. Intramolecular mapping of the immunogenic sites on insulin recognized by guinea pig T and B cells. J. Exptl Med. 145, 726-742 (1977). (Pubitemid 8049622)
103. Rosenthal AS, Rosenwasser LJ, Baskin BL et al. Genetic control of the immune response to insulin. Its dependence upon a macrophage mediated selection of distinct antigenic sites. Adv. Exp. Med. Biol. 98, 447-458 (1978).
104. Schroer JA, Bender T, Feldman RJ, Kim KJ. Mapping epitopes on the insulin molecule using monoclonal antibodies. Eur. J. Immunol. 13(9), 693-700 (1983). (Pubitemid 13012564)
105. Marks A, Yip C, Wilson S. Characterization of two epitopes on insulin using monoclonal antibodies. Mol. Immunol. 22(3), 285-290 (1985). (Pubitemid 15076815)
106. Storch M-J, Petersen K-G, Licht T, Kerp L. Recognition of human insulin and proinsulin by monoclonal antibodies. Diabetes 34, 808-811 (1985). (Pubitemid 15018667)
107. Rathjen DA, Underwood PA. Identification of antigenic determinants on insulin recognized by monoclonal antibodies. Mol. Immunol. 23(4), 441-450 (1986). (Pubitemid 16142916)
108. Storch M-J, Licht T, Petersen K-G, Obermeier R, Kerp L. Specificity of monoclonal anti-human insulin antibodies. Diabetes 36, 1005-1009 (1987). (Pubitemid 17154353)
109. Ottesen JL, Nilsson P, Jami J et al. The potential immunogenicity of human insulin and insulin analogs evaluated in a transgenic mouse model. Diabetologia 37, 1178-1185 (1994). (Pubitemid 24356756)
110. Neubauer HP, Obermeier R, Schnorr G. Immunological properties and biological effectiveness of insulin analogs substituted at position B30. Diabetologia 27, 129-131 (1984). (Pubitemid 14096732)
111. Blundell T, Dodson G, Hodgkin D, Mercola D. Insulin. The structure in the crystal and its reflection in chemistry and biology. Adv. Protein Chem. 26, 279-402 (1972).
112. Nell LJ, Virta VJ, Thomas JW. Recognition of human insulin in vitro by T cells from subjects treated with animal insulins. J. Clin. Invest. 76, 2070-2077 (1985). (Pubitemid 16155496)
113. Glimcher LH, Schroer JA, Chan C, Shevach EM. Fine specificity of cloned insulin-specific T cell hybirdomas. Evidence supporting a role for tertiary conformation. J. Immunol. 131(6), 2868-2874 (1983). (Pubitemid 14208136)
114. Hallden G, Gafvelin C, Mutt V, Jornvall H. Characterization of cat insulin. Arch Biochem. Biophys. 247(1), 20-27 (1986). (Pubitemid 16076918)
115. Seino S, Steiner DF, Bell GI. Sequence of a new world primate insulin having low biological potency and immunoreactivity. Proc. Natl Acad. Sci. USA 84, 7423-7427 (1987).
116. Gennaro WD, Van Norman JD. Quantitation of free, total and antibody-bound insulin in insulin-treated diabetics. Clin. Chem. 21(7), 873-879 (1975).
117. Armitage M, Wilkin T, Wood P, Casey C, Loveless R. Insulin autoantibodies and insulin assay. Diabetes 37, 1392-1396 (1988). (Pubitemid 19035991)
118. Carter P. Preparation of ligand-free human serum for RIA by adsorption on activated charcoal. Clin. Chem. 24(2), 362-264 (1978).
119. Haffner SM, Mykkanen L, Valdez RA et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J. Clin. Endocrinol. Metab. 79(6), 1806-1810 (1994).
120. Nagi DK, Knowler WC, Mohamed-Ali V, Bennett PH, Yudkin JS. Intact proinsulin, des 31,32 proinsulin, and specific insulin concentrations among nondiabetic and diabetic subjects in populations at varying risk of type 2 diabetes. Diabetes Care 21(7), 127-133 (1998). (Pubitemid 28030399)
121. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation. progress and potential. Endocrin. Rev. 19(5). 608-624 (1998).
122. Moore JA, Wroblewski VJ. Pharmacokinetics and metabolism of protein hormones. In: Protein Pharmacokinetics and Metabolism, Pharmaceutical Biotechnology (Volume 1). Ferraiolo BL, Mohler MA, Gloff CA (Eds). Plenum Press, NY, USA 94-98 (1992).
123. Walters E, Henley R, Barnes I. Stability of insulin in normal whole blood. Clin. Chem. 32(1 Pt. 1), 224 (1986).
124. Nowatzke WL, Delhaye R, Reinacher S et al. Stability of insulin in human serum and plasma. Presented at: The AAPS National Biotech Conference. Boston MA, USA, 18-21 June 2006.
125. Hamel FG, Siford GL, Fawcett J et al. Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Metab. 48(5), 611-617 (1999). (Pubitemid 29230522)
126. Wang F, Carabino JM, Vergara CM. Insulin glargine. A systematic review of a long-acting insulin analog. Clin. Ther. 25(6), 1541-1577 (2003). (Pubitemid 36801936)
127. Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of Type 2 diabetes. A review of clinical studies. J. Diabetes Complications 21(3), 196-204 (2007). (Pubitemid 46687071)
128. Again A, Jeandidier N, Gasser F, Grucker D, Sapin R. Glargine blood biotransformation. in vitro appraisal with human insulin immunoassay. Diabetes Metab. 33(3), 205-212 (2007). (Pubitemid 46863409)
129. Ibrahim F, Bagnard G, Boudou P. Differences in circulating insulin levels following glargine administration. Clin. Biochem. 41(6), 429-431 (2008).
130. Kuerzel GU, Shukla U, Scholtz HE et al. Biotransformation of insulin glargine after subcutaneous injection in healthy adults. Curr. Med. Res. Opin. 19(1), 34-40 (2003). (Pubitemid 36378318)
131. Kuerzel G, Sandow J, Seipke G et al. Kinetic and metabolite profile of insulin glargine. Diabetologia 44(Suppl. 1), 798 (2001).
132. DeSilva B, Bowsher RR. Validation of ligand binding assays to support pharmacokinetic assessments of biotherapeutics. In: Ligand- Binding Assays. Development, Validation, and Implementation in the Drug Development Arena. Khan MN, Findlay JW (Eds). John Wiley & Sons Inc, 81-90 (2010).
133. Thway TM, Macaraeg CR, Calamba D et al. Bioanalytical method requirements and statistical considerations in incurred sample reanalysis for macromolecules. Bioanalysis 2(9), 1587-1596 (2010).
134. Fast DM, Kelley M, Viswanathan CT et al. Workshop report and follow-up - AAPS Workshop on Current Topics in GLP Bioanalysis. assay reproducibility for incurred samples - implications of Crystal City recommendations. AAPS J. 11(2), 238-241 (2009).
135. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry, 2nd Edition. W.B. Saunders Co., USA. (1986).
136. Kratz A, Ferraro M, Sluss PM et al. Case records of the mass. General hospital. Laboratory reference values. NEJM 352, 1548-1563 (2004).
137. Gennaro WD, Van Norman JD. Quantitation of free, total and antibody-bound insulin in insulin-treated diabetics. Clin. Chem. 21(7), 873-879 (1975).
138. Steffends AB. Plasma insulin content in relation to blood glucose level and meal pattern in the normal and hypothalamic hyperphagic rat. Physiol. Behav. 5(2), 147-151 (1967).
139. Martin GB, O'Brien JF, Best R et al. Insulin and glucose levels during CPR in the canine model. Annals Emer. Med. 14(4), 293-297 (1985). (Pubitemid 15107190)
140. APIDRA package insert (2009).
141. LEVEMIR package insert (2005).